GLG News by Rituxan Prescribers for NHL: Lymphoma Oncologists (US)

New data with low and high dose of Avastin with Taxoter

esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients'...

Yet another study, although small, report 15 5 incidence of cardiac abnormalities in patients receiving Pfizer's Sutent. The abnormalities persist and are serious in patients with previous history of cardiac disease. Sutent is an efficacious drug, but it has alternative options ( Nexavar and Torisel...

A recent trial showed that Genentech's Avastin when added to Docotaxel , increased time to progression in patients with recurrent breast cancer. This trial confirms results of a previous study and is reported to have better safety profile. Although survival data are still pending, the efficacy results...

GSK's oral topotecan was favorably reviewed in Europe for treatment of recurrent small cell cancer. IV topotecan is used in ovarian cancer , sarcomas, an rarely in hematological malignancies. The indication is quite narrow and oral use is complicated by lack of re-imbursement and poor patient...

In a phase II trial , Pfizer's Sutent produced an overall response arte of 11 % as second line treatment for patients with non-small cell lung cancer. The response rates is similar to approved agents for recurrent patients with an oral "targeted " drug and favorable safety profile. The role would be...

Takeda is collaborating with Effamax to conduct a phase I trial investigating a new erythropoeitin stimulating agent  ( ESA) in anemic patients with refractory solid tumors receiving chemotherapy. The study is well designed and if the new agent has efficacy of Aranesp ( Amgen) and Procrit ( J&...

Anemia represents a common problem in patients treated with chemotherapy.  Although Aranesp and Procrit represented frequently used therapies for the treatment of chemotherapy induced anemia, the recent warnings regarding potential toxicities of these agents limit their use by many physicians. ...

As I medical oncologist, I frequently deal with neuropathic pain caused either directly by tumors or for complications of cancer therapy.  this is a frequent complaint that impairs quality of life for cancer patients.  Current options for treatment all provides suboptimal efficacy and there...

Rituximab is an anti-CD 20 monoclonal antibody with activity in many diseases including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.  The current phase 3 trial provides further support for the use of rituximab in patients with CLL and is the first study to definitively show an improvement...